Vascular Effects of Eplerenone in Coronary Artery Disease with Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial

Clinical Cardiology

Volumn 39, Issue 5, 2016, Pages 285-290

  Sudano, Isabella ^a   Naegele, Matthias ^a   Roas, Susanne ^a   Périat, Daniel ^a   Frank, Michelle ^a   Kouroedov, Alexey ^b   Noll, Georg ^a,b   Lüscher, Thomas F ^a,b   Enseleit, Frank ^a   Ruschitzka, Frank ^a,b   Flammer, Andreas J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; THIAZIDE DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY FLOW MEDIATED DILATATION; CARDIOVASCULAR EFFECT; CELL COUNT; CLINICAL ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; FEMALE; HEART EJECTION FRACTION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ADHESION; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; BRACHIAL ARTERY; DIAGNOSTIC IMAGING; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PATHOPHYSIOLOGY; SWITZERLAND; TIME FACTOR; TREATMENT OUTCOME; VASODILATATION;

AGED; BLOOD PRESSURE; BRACHIAL ARTERY; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PLATELET ADHESIVENESS; SPIRONOLACTONE; STROKE VOLUME; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 84962597112     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22528     Document Type: Article

References (25)

1. Pitt B, Zannad F, Remme WJ, et al,; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-717.
2. Pitt B, Remme W, Zannad F, et al,; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348:2271]. N Engl J Med. 2003; 348: 1309-1321.
3. Pitt B, Pfeffer MA, Assmann SF, et al,; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370: 1383-1392.
4. Güder G, Bauersachs J, Frantz S, et al., Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007; 115: 1754-1761.
5. Ivanes F, Susen S, Mouquet F, et al., Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012; 33: 191-202.
6. Pitt B., Heart failure: the role for mineralocorticoid receptor antagonists. Swiss Med Wkly. 2014; 144: w13959.
7. Farquharson CA, Struthers AD,. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond). 2002; 103: 425-431.
8. Gutiérrez E, Flammer AJ, Lerman LO, et al., Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 2013; 34: 3175-3181.
9. Farquharson CA, Struthers AD,. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000; 101: 594-597.
10. Flammer AJ, Anderson T, Celermajer DS, et al., The assessment of endothelial function: from research into clinical practice. Circulation. 2012; 126: 753-767.
11. Gemignani V, Bianchini E, Faita F, et al., Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating. Ultrasound Med Biol. 2008; 34: 385-391.
12. Spieker LE, Flammer AJ, Amacker N, et al., C-reactive protein influences shear stress-dependent platelet adhesion in patients with familiar hypercholesterolemia and coronary artery disease undergoing LDL apheresis. Thromb Haemost. 2006; 96: 540-542.
13. Ferrari R, Guardigli G, Ceconi C,. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drugs Ther. 2010; 24: 331-339.
14. Frick M, Alber HF, Hügel H, et al., Short- and long-term changes of flow-mediated vasodilation in patients under statin therapy. Clin Cardiol. 2002; 25: 291-294.
15. He FJ, Marciniak M, Carney C, et al., Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives. Hypertension. 2010; 55: 681-688.
16. Epstein M, Calhoun DA,. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011; 13: 644-648.
17. Brown MJ, Williams B, Morant SV, et al,; PATHWAY Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016; 4: 136-147.
18. Favre J, Gao J, Zhang AD, et al., Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol. 2011; 300: H2035-H2043.
19. Fraccarollo D, Berger S, Galuppo P, et al., Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011; 123: 400-408.
20. Lother A, Berger S, Gilsbach R, et al., Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2011; 57: 746-754.
21. Montalescot G, Pitt B, Lopez de Sa E, et al,; REMINDER Investigators. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J. 2014; 35: 2295-2302.
22. Macdonald JE, Kennedy N, Struthers AD,. Effects of spironolactone on endothelial function, vascular angiotensin-converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart. 2004; 90: 765-770.
23. Pfeffer MA, Claggett B, Assmann SF, et al., Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131: 34-42.
24. Fujimura N, Noma K, Hata T, et al,; ROCK Study Group. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther. 2012; 91: 289-297.
25. Struthers A, Krum H, Williams GH,. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008; 31: 153-158.